HOME > TOP STORIES

TOP STORIES

BUSINESS EMA Backs Leqembi after Re-Examination, but for Limited Use

November 15, 2024
REGULATORY MOF Stands Firm on Push for Full-Scale Off-Year Revision in FY2025

November 14, 2024
REGULATORY Kisunla Gets Reimbursement Listing with Daily NHI Price of 8,560 Yen

November 14, 2024
REGULATORY Japan Panel OKs Listing of Kisunla, Tepezza, Quviviq, and Many More

November 14, 2024
BUSINESS Lilly Japan Halts Manufacturing of Strattera over Nitrosamine Impurities

November 14, 2024
REGULATORY DPP to Ruling Bloc: Quickly Scrap Off-Year Drug Price Revisions

November 13, 2024
ORGANIZATION Osaka’s New Life Science Hub to Grow into Full Ecosystem in 5 Years: Operator

November 12, 2024
BUSINESS Moderna Sees CMV, EBV Vaccines as “Significant Assets”: Medical Affairs Chief

November 12, 2024
REGULATORY Anapeine Generics Get Expedited Listing amid Supply Crunch

November 12, 2024
COMMENTARY With 1/4 of Pharma Backers Losing Seats, It’s Time for Industry to Revamp Lobbying Activities

November 11, 2024
REGULATORY MHLW Eyes Extra Budget for Pharma Innovation, Generic Rejig

November 11, 2024
BUSINESS Eisai Cuts Leqembi Sales Target as It Sees “Some Delays” in US Uptake

November 11, 2024
ACADEMIA Private-Academia Collab Yields 8 Pediatric Drug Approvals in Japan

November 8, 2024
REGULATORY Chuikyo Supports Full Rollout of Company Indices for Generics Manufacturers

November 7, 2024
BUSINESS Nxera Pharma Eyes 50 Billion Yen in Global Revenue by 2030: CEO

November 7, 2024
ACADEMIA Alzheimer’s-Related Guidelines Being Revised to Accommodate Kisunla, Rexulti

November 6, 2024
ACADEMIA Japan Crafting Registry of All Hemophilia Patients, Company Use Eyed Too

November 5, 2024
REGULATORY Advisory Panel Backs Transfer of GMP Inspection Authority for New Generics to PMDA

November 5, 2024
REGULATORY PMDA Opens US Office in Washington, D.C.

November 5, 2024
BUSINESS FDA Rolling Submission for Leqembi SC Completed: Eisai

November 5, 2024

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision

By Ken Yoshino

Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…